Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
9,444 total articles
SS&C Technologies (SSNC) is the kind of stock that rarely trends on social media, yet it sits in the workflow of asset managers and financial institutions where automation and AI actually get budget. With steady cash generation, a reasonable valuation for a sticky software franchise, and a technically compressed pullback from the 2025 highs, SSNC o…
Uranium Energy Corp. has ripped to fresh highs with nuclear sentiment heating up, but the stock is also getting technically stretched and still valued like a high-growth story. This trade idea stays constructive while respecting the risk of a pullback: define the level, lean on trend support, and target a retest of the highs with a clear stop if mo…
Natural Resource Partners just backed off its fresh 52-week high, and the dip is landing right on a rising short-term moving average. With low leverage (debt-to-equity ~0.11), strong profitability (ROA ~19%, ROE ~24%), and a dividend yield north of 5% in the ratios data, this is one of the cleaner “buy-the-pullback” setups in the coal royalty/soda …
Copart runs a scaled, online vehicle remarketing platform that monetizes the messy aftermath of accidents and write-offs. The stock has been rebuilding after a sharp drawdown from its 52-week high, while profitability and cash generation remain strong. With bullish momentum signals and a clean balance-sheet profile, the trade idea is a mid-term lon…
PEYUF is trading at $17.63, essentially matching its 52-week high, with bullish MACD momentum and the stock holding above key moving averages. This trade idea leans long: use the recent breakout as a line in the sand, look for follow-through into the next resistance zone, and frame risk around a pullback to the rising 20-day/50-day trend. The divid…
Micron has rerated hard, with MU printing fresh 52-week highs near $412 and pushing RSI into overbought territory. But the market is paying up for something real: a memory upcycle powered by AI infrastructure, tight supply, and improving profitability. This trade idea looks to participate in continued upside while acknowledging the very real risk o…
Carpenter Technology (CRS) sits in a high-performance metals niche that benefits disproportionately when aerospace and defense demand tightens. With the stock near $335 and close to its 52-week high, the setup is a momentum-friendly buy - but you need a defined stop because the valuation is no longer forgiving. This trade idea targets a continuatio…
Salesforce has been repriced as if its best days are behind it, yet the company still throws off substantial free cash flow and trades at valuations that look more like a mature software utility than a platform with multiple re-acceleration levers. With CRM sitting near recent lows, oversold technicals, and reasonable balance sheet leverage, this i…
Crocs (CROX) is down near the lower end of its 52-week range despite still screening like a serious cash-flow business. With EV/EBITDA around 5.5 and price-to-free-cash-flow near 6.2, the stock looks priced for disappointment. The trade idea is to buy near $85.82 with a defined stop under recent support, targeting a move back toward the mid-$90s to…
National HealthCare (NHC) has surged to new 52-week highs, but the stock still looks reasonably valued against its cash generation and improving fundamentals. With bullish technicals, low leverage, and a business tied to durable senior-care demand, this sets up as a mid-term trade where you’re paying for quality, not hype.
Envista (NVST) is trading near its 52-week high with improving momentum and a market that still seems hesitant to pay up for a cleaner FY25 setup. With valuation no longer “cheap” on headline P/E but still reasonable on sales and cash flow metrics, the trade hinges on a continuation move through resistance as investors lean into a potential FY25 be…
Cohen & Steers has sold off from its 52-week high near $91 to about $66, pushing the dividend yield to roughly 3.7% and resetting expectations. For an asset manager tied to real assets and income strategies, that’s an appealing mix if the market rotates back toward yield and defensiveness. The trade: buy the dip near $65.91 with a stop below recent…
Carlisle is a building-envelope winner with strong profitability metrics and real structural tailwinds in insulation, roofing, and weatherproofing. Shares have pulled back sharply from the $435.92 52-week high to ~$349, but trend/momentum indicators remain constructive and liquidity is solid. This trade idea targets a mean-reversion move back towar…
Topicus has the kind of business mix investors usually pay up for: critical vertical market software with recurring revenue and a proven M&A playbook. The stock, however, has been sliding and recently tagged a fresh 52-week low before stabilizing. With TOITF now at $82.76 versus a $144.10 52-week high, bearish momentum looks increasingly priced in.…
Lear is an unglamorous business in a cyclical industry, but the numbers suggest it’s being priced like a permanent value trap. With LEA around $119.91, a ~14x P/E, EV/EBITDA near 5.6, and strong free cash flow ($734.8M), the risk-reward looks attractive for a mid-term move back toward recent highs, as long as the stock can hold key support near $11…
Ambarella is positioning itself as a picks-and-shovels provider for “physical AI” - on-device perception and decision-making in cameras, automotive, and robotics. CES 2026’s CV7 launch (4nm, multi-sensor 8K, higher AI throughput at lower power) is a timely catalyst, and the stock is back near support after a multi-month slide. This trade idea looks…
KKR has sold off to $121.25 with RSI near 36 and price sitting well below key moving averages. That’s the setup. Under the hood, this is a scaled alternative-asset platform with an insurance leg, solid free cash flow ($5.09B), and a $108B market cap that’s pricing in a lot of macro fear. I’m upgrading the view and looking for a mid-term rebound tow…
Vishay (VSH) is a behind-the-scenes supplier of power semis and passive components that show up in industrial power supplies, EV/HEV systems, telecom gear, and more. The stock just pulled back to ~$18.45 after a sharp run, but the trend remains constructive with bullish momentum signals and a clear near-term catalyst on 02/04/2026 (Q4 and FY2025 re…
Robotaxi headlines have pressured sentiment around Uber, but the economics point to a slower, multi-player rollout where demand aggregation, pricing, and marketplace liquidity still matter. With shares around $82 and technicals washed out, this sets up a mid-term long trade toward a reclaim of key moving averages, with clearly defined risk below re…
Abbott just printed a painful post-earnings air pocket and tagged a fresh 52-week low near $105.78. The selloff looks more like a reset of expectations than a permanent impairment: ABT still carries strong profitability (ROE ~27%), low leverage (debt-to-equity ~0.25), and meaningful free cash flow (~$6.9B). With RSI deeply oversold (~16) and heavy …
LLY sold off after an FDA timing delay for its oral GLP-1, and the tape is now treating that as a bigger competitive loss to Novo than it likely is. With the stock sitting near its 10- and 50-day averages and momentum washed out, the setup favors a defined-risk long trade into a potential sentiment rebound and upcoming catalyst window.
CBL has slipped from its recent high and is now trading below short-term moving averages with a subdued RSI. For a mall REIT with a single-digit P/E, mid-single digit dividend yield, and meaningful free cash flow, that pullback looks more like a reset than a breakdown. This is a mid term trade idea built around mean reversion back toward the 20-day…
Satellogic just printed a new 52-week high on heavy volume, and the tape is finally paying attention to its low-cost Earth observation pitch. Even after the spike, the market cap sits around $710M, while the company is pointing toward higher-resolution NextGen satellites and distribution partnerships that can widen demand. This is a momentum-plus-c…
NeoGenomics sits in a sweet spot of cancer testing: it is big enough to be embedded across community oncology workflows, but still small enough that sentiment can swing fast. With shares around $12.82, improving trend signals (RSI 56, price above key moving averages) and meaningful short interest (about 7.9M shares, ~4.9 days to cover), NEO looks s…
Hims & Hers (HIMS) has gone from market darling to market punching bag in less than a year, sliding from a $72.98 high to the high $20s. But the selloff is starting to look more like a reset than a terminal breakdown: RSI is oversold-ish (34.6), price is extended below key moving averages, and short interest remains heavy (67.1M shares as of 12/31/…
